With TNF inhibitors (all: n = 49) | With CS without TNF inhibitors | ||||
---|---|---|---|---|---|
With CS (n = 20) | Without CS (n = 29) | P value* | (n = 22) | P value** | |
Male, n (%) | 5 (25) | 7 (24.1) | 0.6607 | 10 (45.5) | 0.0773 |
Age | 42.2 ± 13.4 | 40.7 ± 14.7 | 0.6989 | 34.1 ± 11.8 | 0.0349 |
Clinical manifestations at diagnosis, n (%) | Recurrent aphthae 20 (10), | Recurrent aphthae 29 (100), | Recurrent aphthae 22 (100), | ||
Skin 20 (100), uveitis 3 (15), genital ulcer 14 (70), arthritis 10 (50), epididymitis 1 (5), digestive tract sores 20 (100), vascular lesion 5 (25), CNS lesion 3 (15) | Skin 26 (89.7), uveitis 3 (10.3), genital ulcer 19 (65.5), arthritis 21 (72.4), digestive tract sores 29 (100), vascular lesion 1 (3.4), CNS lesion 4 (13.8) | Skin 22 (100), uveitis 7 (31.8), genital ulcer 13 (59.1), arthritis 18 (81.8), digestive tract sores 22 (100), vascular lesion 2 (9.1), CNS lesion 3 (13.6) | |||
Type, n (%) | Complete 3 (15), incomplete 17 (85) | Complete 3 (10.3), incomplete 26 (89.7) | 0.8244 | Complete 2 (9.1), incomplete 20 (90.9) | 0.6975 |
Vascular-BD, n (%) | 5 (25) | None | 0.0081* | 2 (9.1) | 0.9163 |
Neuro-BD, n (%) | 2 (10) | 8 (27.6) | 0.1260 | 3 (13.6) | 0.4951 |
HLA-B51 positive (%) | 4 of 18 (22.2) | 6 of 20 (30) | 0.4323 | 3 of 10 (30) | 0.8156 |
Disease duration BD (month) | 83.8 ± 73.5 | 86.6 ± 67.0 | 0.6451 | 48.2 ± 30.0 | 0.0552 |
entero-BD (month) | 55.8 ± 69.3 | 50.1 ± 56.6 | 0.6540 | 28.3 ± 21.2 | 0.5135 |
Site of ulceration, n (%) (overlapping) | Ileum 4 (20), ileocecum 13 (65), ascending colon 5 (25), transverse colon 2 (10), descending colon 4 (20), sigmoid colon 4 (20) | Ileum 6 (20.7), ileocecum 15 (51.7), ascending colon 8 (27.6), transverse colon 7 (24.1), descending colon 5 (17.2), sigmoid colon 7 (24.1), esophagus 1 (3.4) | Ileum 4 (18.2), ileocecum 17 (77.3), ascending colon 5 (22.7), transverse colon 4 (18.2), descending colon 2 (9.1), sigmoid colon 1 (4.5) | ||
Cases with multiple ulceration, n (%) | 7 (35) | 10 (34.5) | 0.9072 | 7 (31.8) | 0.8128 |
Treatment history, n (%) | High-dose CS 9 (45), low-dose CS 9 (45), col 10 (50), MTX 17 (85), SSZ/MS 8 (40), AZ 3 (15), IVCY 2 (10), IFX 3 (15), GLM 3 (15), ETN 1 (5) | High-dose CS 3 (10.3), low-dose CS 3 (10.3), col 19 (65.5), MTX 16 (55.2), SSZ/MS 11 (37.9), AZ 3 (10.3), CsA 1 (34.4), IFX 5 (17.2), GLM 1 (34.5), ETN 3 (10.3), ADA 3 (10.3) | High-dose CS 13 (59.1), col 14 (63.6), MTX 1 (45.5), SSZ/MS 11 (50), AZ 1 (45.5) | ||
Bio naïve, n (%) | 16 (80) | 21 (69.0) | 0.7605 | NA | |
History of relapse, n (%) | 13 (65) | 16 (55.2) | 0.3488 | 11 (50) | 0.4076 |
History of perforation, n (%) | 5 (25) | 4 (13.8) | 0.2654 | 1 (4.5) | 0.1216 |
History of surgery, n (%) | 5 (25) | 1 (3.4) | 0.0595 | 2 (9.1) | 0.6975 |
Concomitant CS dose (mg/day) | 18.7 ± 20.4 median 10, range 2–62.5 | NA | 32.3 ± 16.4 median 30, range 6–60 | 0.0069** | |
Concomitant drugs | MTX 17 (85), col 4 (20), MS/SSZ: 3 (15), AZ 1 (5) | MTX 23 (79.3), col 14 (48.3), MS/SSZ 4 (13.8), AZ 3 (10.3) | MS/SSZ 11 (50), col 14 (63.6), AZ 1 (4.5), MTX 1 (4.5) | ||
Introduced TNF-i | IFX 15 (75), ETN 4 (20), ADA 1 (5) | IFX 17 (58.6), ETN 1 (3.4), ADA 9 (31.0), GLM 2 (6.9) | NA | ||
DAIBD | 70.7 ± 38.4, median 62.5, range 50–93 | 60.5 ± 32.2, median 60.0, range 37.5–80 | 0.3045 | 85.2 ± 29.6, median 87.5, range 35–135 | 0.0139** |
General well-being, n (%) | Fair 10 (50), poor 3 (15), very poor 1 (5) | Fair 19 (65.5) | Fair 18 (81.8) | ||
Fever (≧ 38 °C), n (%) | 6 (30) | 3 (10.3) | 11 (50) | ||
Extra-intestinal manifestation, n (%) | Oral 12 (60), genital ulcer 7 (35), eye 0, skin 9 (45), arthralgia 5 (25), vascular 5 (25), CNS 1 (5) | Oral 10 (34.5), genital ulcer 7 (24.1), eye 0, skin 7 (24.1), arthralgia 8 (27.6), vascular 0, CNS 7 (24.1) | Oral 15 (68.2), genital ulcer 5 (22.7), eye 0, skin 16 (72.7), arthralgia 6 (27.2), vascular 2 (9.1), CNS 1 (4.5) | ||
Abdominal pain, n (%) | Mild 8 (40), moderate 6 (30), severe 1 (5) | Mild 11 (37.9), moderate 4 (13.8) | Moderate 18 (81.8), severe 2 (9.1) | ||
Abdominal mass, n (%) | 1 (5) | None | None | ||
Abdominal tenderness, n (%) | Mildly 7 (35), moderately or severely 10 (50) | Mildly 14 (48.3), moderately or severely 4 (13.8) | Mildly 3 (13.6), moderately or severely 17 (77.3) | ||
Intestinal complication, n (%) | Perforation 4 (20), abscess 1 (5), obstruction 3 (15) | Perforation 1 (3.4) | None | ||
No of liquid stool in 1 week, n (%) | 1–7 times: 6 (30), 8–21 times: 3 (15), 22–35 times: 3 (15) | 1–7 times: 7 (24.1), 8–21 times: 2 (6.9), 22–35 times: 3 (10.3) | 1–7 times: 2 (9.1), 8–21 times: 7 (31.8), ≧ 36 times: 4 (18.2) |